Hong Kong Stock Alert | BRAINAURORA-B (06681) Surges Over 14% as Brain-Computer Interface Industry Receives Policy Support, Company's Cognitive Disorder Digital Therapy Product Holds First-Mover Advantage

Stock News
09/30

BRAINAURORA-B (06681) surged over 14%, rising 14.08% to HK$8.5 with trading volume of HK$311 million as of press time.

On the news front, Minister of Industry and Information Technology Li Lecheng recently stated at the opening ceremony of the 25th China International Industry Fair that China will implement actions to cultivate emerging industries and create new growth drivers. The initiative will coordinate technological innovation, large-scale development, and application scenario construction to accelerate the development of emerging pillar industries. China will also establish investment growth mechanisms for future industries, strengthen frontier technology research and development and application promotion, and open new tracks including humanoid robots, brain-computer interfaces, metaverse, and quantum information, while creating future industry pilot zones.

Notably, the National Medical Products Administration recently approved and released the medical device industry standard "Medical Devices Using Brain-Computer Interface Technology - Terminology." This represents China's first brain-computer interface medical device standard, laying the foundation for high-quality development of the brain-computer interface medical device industry. The standard will be officially implemented on January 1, 2026.

BRAINAURORA's core product is a brain function information management platform software system, which is China's first regulatory-approved digital therapy product for cognitive disorders. The company combines brain science with artificial intelligence technology, and its core product system features unique technological advantages including virtual human technology and AI technology. As China's first company to develop medical-grade digital therapy products targeting cognitive disorders, it holds first-mover advantages.

The company's core product has been included in provincial medical insurance reimbursement catalogs in 30 Chinese provinces. The company has successfully helped over 120 hospitals establish cognitive centers in China, including multiple leading hospitals certified as "National Medical Centers," which helps enhance product accessibility and market promotion.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10